ZCI
ARQT icon

Zevenbergen Capital Investments’s Arcutis Biotherapeutics ARQT Stock Holding History

Zevenbergen Capital Investments’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-357,490
Closed -$8.42M – 111
2026
Q1 		$8.42M Sell
357,490
-60,545
-14% -$1.55M 0.24% 58
2025
Q4 		$12.1M Buy
+418,035
New +$10.7M 0.27% 56

Other funds holding ARQT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
PL
Perpetual Ltd Sydney, New South Wales, Australia $7B AUM 19.75% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
JAFL
Jay A. Fishman Ltd Troy, Michigan $1.26B AUM 31.39% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

Zevenbergen Capital Investments's ARQT Position: Q2 2026 in Review

Zevenbergen Capital Investments sold out of Arcutis Biotherapeutics (ARQT) in Q2 2026, closing a stake of 357,490 shares — an estimated $8.42M sold.

Zevenbergen Capital Investments first reported a position in ARQT in Q4 2025 and held it in 2 quarters. The position peaked at $12.1M in Q4 2025. 95 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Zevenbergen Capital Investments reported no remaining Arcutis Biotherapeutics position as of Q2 2026 after selling out during the quarter.
  • Zevenbergen Capital Investments sold 357,490 Arcutis Biotherapeutics shares in Q2 2026, an estimated $8.42M.
  • Zevenbergen Capital Investments first reported a position in Arcutis Biotherapeutics in Q4 2025 and held it in 2 quarters.
  • Zevenbergen Capital Investments's Arcutis Biotherapeutics position peaked at $12.1M in Q4 2025.
  • 95 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Zevenbergen Capital Investments's 13F filing for Q2 2026, filed 16 Jul 2026.